ArticleBMC psychiatry2025
Construction of diagnostic model and subtype analysis of major depressive disorder based on PANoptosis key genes.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cannabidiol modulates spontaneous recovery through distinct and conserved transcriptomic signatures in mPFC subregions.Communications biology · 2026Article
- Identification of a novel PANoptosis-associated prognostic signature and immune landscape analysis in neuroblastoma with experimental validation.Frontiers in immunology · 2026Article
- Cell death pathways in the pathogenesis of depression: mechanisms and therapeutic implications.Frontiers in cell and developmental biology · 2026Review
- Deciphering the mechanistic involvement of PANoptosis in FC-MDD comorbidity through the gut-brain axis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMajor depressive disorder (MDD) is a serious neuropsychiatric disorder. While emerging evidence suggests that PANoptosis may play a role in MDD pathogenesis, the precise involvement of PANoptosis-related genes remains unclear.
methodsThe study conducted a systematic bioinformatics investigation utilizing the GSE98793 dataset. First, we identified differentially expressed PANoptosis-related genes (DE-PRGs). Second, Gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were carried out based on DE-PRGs. Additionally, Random Forest analysis, LASSO regression analysis, immune infiltration analysis, consensus cluster analysis, and single sample genome enrichment analysis were performed. Finally, the expression levels of PANoptosis key genes (PKGs) in MDD were verified using qRT-PCR.
resultsEight PKGs associated with MDD were identified: TRAF1, TNFSF13, TLR2, SH2D1A, RNF144B, ICAM1, HK2, and ADA. Moreover, these PKGs enabled construction of a diagnostic model for MDD PANoptosis risk and stratification of MDD patients into two distinct PANoptosis subtypes (cluster 1 and cluster 2) with differential immune characteristics. Notably, RNF144B and HK2 demonstrated neutrophil-stimulating potential and significant upregulation in MDD patients.
conclusionThis study established a PANoptosis-based diagnostic framework for MDD and identified PANoptosis-stratified MDD subtypes, providing compelling evidence for PANoptosis-mediated immune dysregulation in MDD pathogenesis. These results offered a novel perspective for the diagnosis and management of MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.